Purpose | Dosage Range | Frequency | Administration |
---|---|---|---|
Stimulate LH Release | 0.01-3.0 μg/kg | Single dose | Intravenous bolus |
Increase LH Pulse Frequency | 1.5-4 μg/kg/h | Continuous infusion | Intravenous infusion |
General Research | 1-10 nmol | As per protocol | Subcutaneous/Intravenous |
2. What is Kisspeptin-10?
Kisspeptin-10 is a synthetic decapeptide and the shortest biologically active fragment of the kisspeptin family. Key points:
Kisspeptin-10 works through several mechanisms:
Binds to the G protein-coupled receptor KISS1R (GPR54)
Stimulates GnRH release from hypothalamic neurons
Increases the amplitude of GnRH pulses
Enhances LH and FSH release from the pituitary gland
Modulates the hypothalamic-pituitary-gonadal (HPG) axis
Influences the timing of puberty onset
Regulates fertility and reproductive function
Potently stimulates LH secretion in both men and women
Increases LH pulse frequency and amplitude
Elevates testosterone levels in men
Potential therapy for infertility
May help treat hypogonadotropic hypogonadism
Could be used to trigger ovulation in assisted reproduction
Critical role in the onset of puberty
Potential treatment for precocious or delayed puberty
May influence appetite and body weight
Potential links to obesity and metabolic disorders
Affects expression of neuropeptide Y (NPY)
Modulates brain-derived neurotrophic factor (BDNF) levels
Influences serotonin and dopamine levels in the hypothalamus
Effective dose range: 0.01-3.0 μg/kg
Maximum response typically seen at 1 μg/kg
Dose range: 1.5-4 μg/kg/h
Lower doses (1.5 μg/kg/h) allow for observation of LH pulsatility
In vitro studies: 1 nM - 10 μM range
Animal studies: varies by species and protocol
Reconstitute lyophilized Kisspeptin-10 with sterile water or saline
Use sterile equipment for preparation and administration
Calculate dosage based on body weight or research protocol
For bolus injections, administer over 1 minute
For infusions, use appropriate pump systems
Most common method for acute studies
Rapid onset of action (peak LH within 30-45 minutes)
Used for studying prolonged effects
Allows for manipulation of LH pulse patterns
Less common, but used in some studies
May have different pharmacokinetics compared to IV
GnRH antagonists block Kisspeptin-10 effects, confirming mechanism of action
Testosterone may modulate responsiveness to Kisspeptin-10
Well-tolerated in human trials
No serious adverse effects reported at studied doses
Potential side effects may include injection site reactions, headache
Not approved by the FDA for human use
Legal status varies by country and jurisdiction
Often restricted to research or medical use
In the US, it's legal to possess for research purposes but not for human consumption
Store lyophilized powder at -20°C (-4°F)
Once reconstituted, store at 2-8°C (36-46°F)
Use within 24-48 hours after reconstitution
Protect from light and excessive heat
Always use sterile techniques when handling
Effects on LH levels can be seen within 30-45 minutes of IV administration.
While showing promise, Kisspeptin-10 is not yet approved for fertility treatment. Research is ongoing.
Kisspeptin-10 offers a more physiological approach to stimulating the reproductive axis compared to direct GnRH or gonadotropin administration.
Long-term safety data is limited. More research is needed to establish its safety profile for extended use.
Kisspeptin-10 shows significant promise as a potent stimulator of reproductive hormone release, with potential applications in fertility treatment and reproductive endocrinology research. The typical dosage range of 0.01-3.0 μg/kg for bolus administration and 1.5-4 μg/kg/h for continuous infusion appears effective for most research applications. However, its use should be approached cautiously due to limited long-term human safety data and varying legal status worldwide. As with any experimental compound, thorough research and professional consultation are essential before use. The potential of Kisspeptin-10 in reproductive medicine and endocrinology warrants further investigation, particularly in larger, long-term human trials.
George JT, et al. (2011). Kisspeptin-10 is a potent stimulator of LH and increases pulse frequency in men. J Clin Endocrinol Metab, 96(8), E1228-E1236.
Dhillo WS, et al. (2005). Kisspeptin-54 stimulates the hypothalamic-pituitary gonadal axis in human males. J Clin Endocrinol Metab, 90(12), 6609-6615.
Jayasena CN, et al. (2010). The effects of kisspeptin-10 on reproductive hormone release show sexual dimorphism in humans. J Clin Endocrinol Metab, 95(5), E82-E88.
Pinilla L, et al. (2012). Kisspeptins and reproduction: physiological roles and regulatory mechanisms. Physiol Rev, 92(3), 1235-1316.
Skorupskaite K, et al. (2014). The effects of neurokinin B upon gonadotrophin release in women with hypothalamic amenorrhoea. Clin Endocrinol (Oxf), 80(3), 430-438.
Disclaimer
Peptideresearcher.com contains information about products intended for research and laboratory use only, unless otherwise explicitly stated. All content is for educational purposes and is not meant to substitute for professional medical advice. Peptideresearcher.com strives to ensure that all information presented is accurate and complies with national and international standards, but it is not guaranteed. The content provided is not intended to diagnose, treat, cure, or prevent any disease or condition.
Peptideresearcher.com does not offer medical diagnoses or prescriptions. Any product information shared is solely for research purposes and should be used by qualified professionals only. We advise all users to consult with a healthcare professional before using any peptides, supplements, or medications mentioned on this site. All opinions expressed are those of the individual authors and may not reflect the opinions of Peptideresearcher.com.
Copyright 2024 - Peptide Researcher
Your access to Peptideresearcher.com is subject to our Terms of Use